Cyclophosphamide
Recurrent Childhood Brain Stem Glioma
National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Childhood Brain Stem Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Julie Krystal | Phase 2 | BB |
Eloxatin National Cancer Institute (NCI) | Phase 2 | BB |
Cediranib Pediatric Brain Tumor Consortium | Phase 1/2 | B |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 1/2 | B |
Veliparib National Cancer Institute (NCI) | Phase 1/2 | B |
View all 30 →
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →